Autolus Therapeutics (NASDAQ:AUTL) Given New $11.00 Price Target at Needham & Company LLC

Autolus Therapeutics (NASDAQ:AUTL) had its price target upped by investment analysts at Needham & Company LLC from $10.00 to $11.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other analysts have also issued reports on AUTL. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research report on Wednesday, September 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, October 8th. Finally, Wall Street Zen cut Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.67.

Autolus Therapeutics Price Performance

Shares of AUTL opened at $1.67 on Monday. The firm has a market cap of $444.45 million, a P/E ratio of -2.01 and a beta of 2.01. Autolus Therapeutics has a 1 year low of $1.11 and a 1 year high of $2.80. The stock has a 50 day simple moving average of $1.48 and a two-hundred day simple moving average of $1.78.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%.The business had revenue of $21.19 million during the quarter, compared to the consensus estimate of $21.08 million. On average, equities analysts anticipate that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. grew its position in shares of Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after buying an additional 11,381 shares during the last quarter. Vident Advisory LLC purchased a new stake in Autolus Therapeutics in the first quarter worth $241,000. Jane Street Group LLC boosted its holdings in Autolus Therapeutics by 809.4% in the first quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock valued at $159,000 after acquiring an additional 91,222 shares in the last quarter. Atle Fund Management AB boosted its holdings in Autolus Therapeutics by 130.5% in the second quarter. Atle Fund Management AB now owns 1,105,461 shares of the company’s stock valued at $2,520,000 after acquiring an additional 625,817 shares in the last quarter. Finally, Avanza Fonder AB increased its position in Autolus Therapeutics by 151.6% during the 2nd quarter. Avanza Fonder AB now owns 53,522 shares of the company’s stock valued at $122,000 after purchasing an additional 32,246 shares during the period. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.